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Abstract
Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom sever-
ity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 
inhibitor approved in the United States for treatment of patients with intermediate-2 or high-risk myelofibrosis. The single-arm, 
phase II JAKARTA2 trial assessed fedratinib 400 mg/d (starting dose) in patients with myelofibrosis previously treated with ruxoli-
tinib. Patient-reported changes in myelofibrosis symptom severity using the modified Myelofibrosis Symptom Assessment Form 
(MFSAF), and overall HRQoL and functional status using the EORTC QLQ-C30, were evaluated at each cycle. Clinically meaningful 
changes from baseline HRQoL scores were based on effect sizes. Ninety patients were MFSAF-evaluable. Myelofibrosis symptoms 
were mild-to-moderate at baseline. Patients showed statistically significant and clinically meaningful improvements in total symptom 
scores from baseline on the MFSAF at all post baseline visits through the end of cycle 6 (EOC6). Baseline global health status/QoL 
and functional domain scores on the EORTC QLQ-C30 were meaningfully worse than in the general population. At EOC6, 44% of 
patients reported clinically meaningful improvements in global health status/QoL, and 30%–53% of patients experienced clinically 
meaningful improvement in QLQ-C30 functional domains across post baseline timepoints. Over 80% of ongoing patients perceived 
fedratinib as beneficial on the Patient’s Global Impression of Change questionnaire. Fedratinib effects were consistent among prog-
nostically relevant patient subgroups. Patients with myelofibrosis previously treated with ruxolitinib experienced clinically meaningful 
improvements in myelofibrosis symptom burden, overall HRQoL, and functional status in the first 6 months of fedratinib treatment.
Introduction
Myelofibrosis (MF) is a serious, life-threatening myelopro-
liferative neoplasm (MPN) characterized by stem cell-derived 
clonal myeloproliferation, abnormal cytokine expression, bone 
marrow fibrosis, splenomegaly, extramedullary hematopoie-
sis, constitutional symptoms, cachexia, leukemic progression, 
and shortened survival.1 Patients with MF can experience sub-
stantially compromised health-related quality of life (HRQoL) 
as a result of disease-related constitutional symptoms (night 
sweats, fatigue, and weight loss), symptoms resulting from 
hepatosplenomegaly (early satiety, pain under the ribs on the 
left side, and abdominal discomfort), treatment-related toxic-
ities, and the need for blood transfusions.2,3 Patients with MF 
report worse HRQoL than those with other BCR-ABL-negative 
MPNs (polycythemia vera [PV] and essential thrombocythe-
mia [ET]).4 Until recently, ruxolitinib, a JAK1/JAK2 inhibitor, 
was the only approved treatment for intermediate- or high-risk 
MF. Ruxolitinib treatment has been shown to induce improve-
ments in spleen volume and severity of MF symptoms, but 
some patients may discontinue ruxolitinib within a few years 
due to loss of response or tolerability concerns.5,6 In the phase 
III COMFORT-I and COMFORT-II clinical trials, ruxolitinib 
discontinuation rates in patients with MF were approximately 
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50% at 3 years and ~75% at 5 years.7–10 Prognosis after ruxoli-
tinib failure is generally poor; median survival after treatment 
discontinuation can range from 6 months to 2 years.6,11,12
Fedratinib (INREBIC) is an oral, selective inhibitor with 
activity against wild-type and mutationally activated JAK2 and 
FLT3.13 The National Comprehensive Cancer Network Clinical 
Practice Guidelines for MPNs currently recommend fedratinib 
(400 mg/d QD) and ruxolitinib (5–20 mg/d BID, depending on 
pretreatment platelet count) as initial MF treatment for patients 
with platelet counts of ≥ 50 × 109/L, and fedratinib is recom-
mended as the second-line therapy for patients previously treated 
with ruxolitinib.14 The single-arm, phase II JAKARTA2 trial 
assessed the safety and efficacy of fedratinib 400 mg/d (starting 
dose) in patients with intermediate- or high-risk MF previously 
exposed to ruxolitinib.15 Patients in JAKARTA2 generally had 
advanced MF disease features, including low platelet counts 
and hemoglobin levels and substantial splenomegaly, and had 
received multiple prior MF-directed therapies. The primary end-
point of the JAKARTA2 study was the spleen volume response 
rate after 6 cycles of fedratinib therapy, defined as the propor-
tion of patients achieving a spleen volume reduction of ≥ 35% 
from baseline at the end of treatment cycle 6 (EOC6). Despite 
prior treatment with ruxolitinib, 31% of patients enrolled in 
JAKARTA2 achieved a spleen volume response at EOC6, which 
is similar to the spleen volume response rate in JAK-inhibitor-
naïve patients receiving fedratinib in the placebo-controlled 
phase III JAKARTA trial.15,16 Patient-reported changes in MF 
symptom severity and HRQoL were secondary and explor-
atory endpoints of JAKARTA2. Described here are results of 
three patient-reported assessments of: (1) the impact of fedra-
tinib on MF-related symptom burden, (2) overall HRQoL and 
functional status, and (3) perceptions of the overall benefit of 
treatment, during the first 6 fedratinib treatment cycles in the 
JAKARTA2 trial.
Methods
Study design and eligibility criteria
The phase II, international, multicenter, open-label, single-arm 
JAKARTA2 study was conducted at 40 sites in 10 countries. The 
study protocol was approved by relevant independent ethics com-
mittees or institutional review boards at each site. All patients 
provided written informed consent before study participation. 
The study is registered on ClinicalTrials.gov (NCT01523171).
Detailed study design and eligibility criteria have been 
described previously.15,17 Briefly, eligible patients were adults 
with primary, post-PV or post-ET MF; Dynamic International 
Prognostic Scoring System (DIPSS)18 defined intermediate-1 
(with symptoms), intermediate-2, or high risk disease; palpa-
ble splenomegaly ≥ 5 cm below the left costal margin; Eastern 
Cooperative Oncology Group (ECOG) performance status 
scores ≤ 2; and platelet counts ≥ 50 ×109/L. Although no formal 
criteria for ruxolitinib failure existed at the time of study initi-
ation, all patients must have been considered by their treating 
investigator to be resistant to ruxolitinib following ≥ 14 days 
of therapy, or intolerant to ruxolitinib following any duration 
treatment (Supplemental Digital Figure 1, http://links.lww.com/
HS/A145). All patients were to receive oral fedratinib at a start-
ing dose of 400 mg/d for at least 6 continuous 28-day treatment 
cycles. Fedratinib dose escalation to 600 mg/d was permitted for 
patients who showed a < 50% reduction in spleen size by palpa-
tion from baseline at the end of cycle 2 or cycle 4.
Myelofibrosis symptom assessment form
The myelofibrosis symptom assessment form (MFSAF)3 is an 
evidence-based brief inventory used to measure symptomatic 
response to treatment from the patient’s perspective. The 
JAKARTA2 study employed a modified version of the MFSAF 
(version 2.0) comprising 6 key MF symptoms: night sweats, pru-
ritus, early satiety, pain under ribs on the left side, abdominal dis-
comfort, and bone or muscle pain, each scored from 0 (absent) 
to 10 (worst imaginable). During the 6-cycle treatment period, 
patients were to complete the MFSAF by electronic diary once-
daily for 7 days before the beginning of each cycle, beginning 7 
days before cycle 1, day 1 (C1D1; “baseline”), and prior to the 
EOC6. The weekly total symptom score (TSS) was the average 
of the nonmissing daily TSS during the 7 days preceding each 
post baseline visit. Scores were nonmissing if the daily TSS was 
reported in ≥ 5 of those 7 days. Weekly TSS ranged from 0 to 60, 
with a higher score indicating a worse level of symptomology.
The modified MFSAF endpoints in JAKARTA2 included 
mean symptom score changes from baseline and symptom 
response rate (defined as the proportion of patients with a 
TSS reduction of ≥ 50% from baseline) at each post baseline 
visit, time to first symptom response, and durability of symp-
tom responses. These endpoints were assessed among patients 
in the modified MFSAF-evaluable population; that is, patients 
who had an evaluable assessment at baseline and received 
at least 1 full cycle of fedratinib therapy. The magnitude of 
changes from baseline in symptom scores at each post baseline 
visit was evaluated using effect sizes, calculated using Hedges’ 
g19; a medium effect size of ≥ 0.5, which represents one-half 
of the SD, is a commonly used threshold to indicate a “clini-
cally meaningful” change from baseline at a given visit when 
a threshold is not well-established.20 Modified MFSAF score 
changes from baseline were also assessed for statistical signif-
icance using a 1-sample, 2-sided t-test. In responder analyses, 
the proportions of patients achieving reductions (improve-
ments) from baseline scores of ≥ 50% in TSS or in individual 
symptom scores at each visit were assessed among MFSAF-
evaluable patients with a baseline TSS > 0. An MFSAF-
evaluable patient with a missing score at a post baseline 
assessment was deemed a nonresponder at that timepoint. The 
95% confidence intervals (95% CIs) for symptom responses 
were estimated using Clopper–Pearson methods. Time to first 
symptom response was defined as the time from baseline to 
the first visit at which a patient achieved a TSS reduction of 
≥ 50% from baseline, and was estimated using Kaplan–Meier 
methods. Definitive symptom improvement was defined as 
≥ 2 consecutive visits at which a patient achieved a symptom 
response. Durability of the symptom response was measured 
by the number of cycles at which individual patients achieved 
a symptom response through EOC6.
Compliance rate at each visit was calculated as the number of 
patients who had received at least 1 full cycle of fedratinib treat-
ment and had a nonmissing weekly TSS, divided by the number 
of patients on-study at that visit. Completion rates were calcu-
lated by dividing the number of patients with nonmissing TSS 
at a given visit by the number of patients in the intent-to-treat 
(ITT) population at baseline.
European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life 
Questionnaire Core 30
Overall HRQoL and functional status were evaluated using 
the Quality of Life Questionnaire Core 30 (QLQ-C30), a self-ad-
ministered questionnaire that measures HRQoL in patients with 
cancer.21 The QLQ-C30 consists of 30 items in 15 HRQoL 
domains, including a 2-item global health status/QoL domain, 
5 multiitem functional domains (physical, role, emotional, cog-
nitive, and social functioning), 3 multiitem symptom domains 
(fatigue, nausea/vomiting, and pain), and 6 single-item domains 
assessing various symptoms and perceived financial impact of 
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disease. The primary QLQ-C30 domain of interest was global 
health status/QoL. Each domain score ranged from 0 to 100; 
higher scores on the global health status/QoL domain and the 
5 functional domains indicate better overall HRQoL and level 
of functioning, whereas higher symptom domain scores repre-
sent worse symptomatology. During the 6-cycle treatment phase 
in these analyses, patients completed the QLQ-C30 on day 1 
of each treatment cycle and at EOC6. A QLQ-C30 domain 
score was included in analyses if responses were available for 
≥ 50% of items in that domain; otherwise, it was considered 
missing. The QLQ-C30–evaluable population included patients 
with nonmissing QLQ-C30 scores at baseline (C1D1) who had 
received ≥ 1 dose of fedratinib on-study. The QLQ-C30 com-
pliance rate was calculated at each visit by dividing the number 
of patients who received at least 1 dose of fedratinib and had 
an evaluable QLQ-C30 assessment by the number of ongoing 
patients at that visit, and the completion rate was the number of 
patients with nonmissing scores at a given visit divided by the 
number of patients in the ITT population.
QLQ-C30 endpoints included observed mean changes from 
baseline in domain scores and the rate of clinically meaning-
ful improvement in QLQ-C30 domain scores at each post 
baseline visit. Changes from baseline in QLQ-C30 domain 
scores at each post baseline visit were assessed by effect sizes, 
calculated using Hedges’ g,19 and P values were calculated 
using a 1-sample, 2-sided t-test. A change from baseline of 
≥ 10 points on any QLQ-C30 domain has been considered 
clinically meaningful.22 In responder analyses, rates of clini-
cally meaningful changes from baseline in domain scores were 
assessed among patients with nonmissing domain scores at 
each visit, and corresponding 95% CIs were estimated using 
Clopper–Pearson methods.
Patient’s global impression of change
The patient’s global impression of change (PGIC) comprises 
1 item from the clinical global impressions scale23 that assesses 
patients’ perceptions of changes in MF symptom severity over 
time to provide an overall sense of whether treatment is benefi-
cial. Global impression of change during treatment is measured 
using a 7-point Likert scale associated with responses to the state-
ment, “Since the start of the treatment you have received in this 
study, your MF symptoms are…” Response options are: very 
much improved (level 1), much improved, minimally improved, 
no change, minimally worse, much worse, and very much worse 
(level 7). The PGIC questionnaire was administered at C4D1, 
C6D1, and EOC6. Because the PGIC was not assessed at baseline, 
PGIC outcomes were assessed at each timepoint among patients 
in the ITT population who were still ongoing at each timepoint. 
PGIC scores were summarized into 3 categories representing 
perceived change from start of treatment at each visit: improved 
(levels 1–3); no change (level 4); and worsened (levels 5–7). The 
95% CIs for the proportion of patients in each category at each 
timepoint were estimated using Clopper–Pearson methods.
Subgroup analyses
To understand the potential impact of patient- and dis-
ease-related characteristics at baseline on patient-reported 
outcomes during fedratinib therapy, subgroup analyses were 
conducted assessing the proportions of patients who achieved 
a ≥ 50% reduction from baseline in TSS on the modified 
MFSAF, and proportions of patients who had meaningful 
improvement from baseline in QLQ-C30 global health status/
QoL domain score (≥ 10-point increase), at EOC6. Rates of 
clinically meaningful improvement in TSS and global health 




In all, 97 patients were enrolled in JAKARTA2 and received 
fedratinib 400 mg/d (starting dose). The MFSAF-evaluable pop-
ulation comprised 90 patients (93%) with an evaluable weekly 
TSS at baseline. Compliance rate on the modified MFSAF 
remained high (> 90%) at all post baseline visits through 
EOC6 (Supplemental Digital Figure 2, http://links.lww.com/
HS/A146), with an overall rate of 98%. At EOC6, the MFSAF 
compliance rate was 93% (51/55) and the completion rate was 
57% (51/90). The QLQ-C30–evaluable population included 94 
patients (97%), and compliance rates were also high (≥ 90%) 
at all post baseline assessments through EOC6 (Supplemental 
Digital Figure 2, http://links.lww.com/HS/A146). At EOC6, 
94% (50/53) of eligible patients were QLQ-C30 compliant and 
the completion rate was 52% (50/97).
Baseline demographic and disease characteristics for the 
modified MFSAF-evaluable population (Supplemental Digital 
Table 1, http://links.lww.com/HS/A144) were generally com-
parable to those for all enrolled patients (ITT population). At 
study entry, median age was 67 years, over one-half of modi-
fied MFSAF-evaluable patients had a diagnosis of primary MF 
(53%), and most had intermediate-2 risk MF (51%). Median 
time from MF diagnosis was 4.0 years (range 0.3–21.0), 
median spleen volume was 2894 mL (784–7815), and median 
duration of prior ruxolitinib exposure was 11.1 months 
(0.1–62.4). All patients in the modified MFSAF-evaluable 
cohort reported experiencing constitutional MF symptoms at 
baseline.
Table 1.
Baseline Scores on the Modified MFSAF and QLQ-C30 Instruments
Instrument Measure
JAKARTA2
Reference Value From  
General Population
Mean [SD] Mean
Modified MFSAF N = 90*  
 Total symptom score 20.7 [12.1] NR
  Night sweats 3.4 [2.6] NR
  Pruritus 2.3 [2.5] NR
  Abdominal discomfort 4.1 [2.8] NR
  Early satiety 4.4 [2.6] NR
  Pain under ribs on left side 2.9 [2.7] NR
  Bone or muscle pain 3.6 [2.8] NR
 EORTC QLQ-C30 N = 97 N = 11,34324
  Global health/QoL 44.6 [22.2] 66.2
  Physical functioning 60.5 [22.6] 82.9
  Role functioning 51.3 [30.7] 83.6
  Emotional functioning 70.8 [23.7] 79.7
  Cognitive functioning 76.3 [23.0] 86.9
  Social functioning 62.2 [31.1] 88.4
  Fatigue 59.1 [26.5] 25.9
  Nausea/vomiting 11.6 [17.3] 3.0
  Pain 43.4 [32.4] 24.2
  Dyspnea 41.9 [32.6] 17.0
  Insomnia 47.7 [35.2] 25.8
  Appetite loss 41.9 [31.1] 7.3
  Constipation 18.9 [25.5] 10.9
  Diarrhea 20.7 [26.2] 6.8
  Financial difficulties 18.5 [27.9] 8.5
*The modified MFSAF HRQoL-evaluable population comprised patients with at least 1 full cycle of 
fedratinib treatment who had a non-missing TSS score at baseline (ie, ≥ 5 of the 7 daily TSS were 
not missing).
EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire, Core 30; HRQoL = health-related quality of life; MFSAF = myelofibrosis symptom 
assessment form; NR = not reported; QoL = quality of life; TSS = total symptom score.
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Myelofibrosis symptom assessment form
Baseline mean [±SD] TSS on the modified MFSAF was 20.7 
[12.1]. Mean scores for the 6 individual MFSAF symptoms at 
baseline ranged from 2.3 to 4.4, indicating mild to moderate MF 
symptom severity (Table 1), with the highest scores reported for 
early satiety (4.4 [2.6]) and abdominal discomfort (4.1 [2.8]).
During the first 6 cycles of fedratinib treatment, patients 
reported significant (P < 0.05) mean TSS improvements from 
baseline beginning at the cycle 2 assessment followed by all 
subsequent scheduled post baseline visits through EOC6, with 
clinically meaningful medium effect sizes (at least –0.5) at each 
timepoint (Figure 1). At EOC6, mean [±SD] TSS was 11.8 [8.2], 
representing a clinically meaningful (effect size –0.68) mean 
change from baseline of –8.3 [1.3] points for the 51 patients 
with data at both baseline and EOC6. Significant (P < 0.05) 
improvements from baseline were also reported for all 6 indi-
vidual MFSAF symptoms at all time points through EOC6. 
Changes from baseline were clinically meaningful for most 
individual symptoms, with medium effect sizes at every visit for 
night sweats and early satiety, at all but C2D1 for pain under the 
ribs on left side, and at one-half of all visits for abdominal dis-
comfort. Effect sizes for pruritis and bone or muscle pain were 
at least –0.20 at almost all post baseline assessments. At EOC6, 
mean symptom scores were clinically meaningfully improved 
from baseline for early satiety (effect size –0.69), night sweats 
Figure 1. Changes from baseline in MFSAF total symptom score and corresponding effect sizes. 
Figure 2. Effect sizes for changes from baseline in MFSAF total symptom score and the 6 individual MFSAF symptoms at the end of cycle 6.
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(–0.68), and pain under the ribs on left side (–0.59), and effect 
sizes trended toward clinically meaningful for abdominal dis-
comfort (–0.47) and pruritus (–0.43) (Figure 2).
In responder analyses, 27%–36% of MFSAF-evaluable 
patients had TSS reductions of ≥ 50% from baseline across 
post baseline visits through EOC6 (Figure 3A). Of all modified 
MFSAF-evaluable patients, durable responses were attained by 
38% of patients who achieved ≥ 50% reductions in TSS score 
from baseline at ≥ 2 post baseline timepoints. Median time to ≥ 
50% reduction in TSS was 20 weeks (95% CI 12, 24) (Figure 4) 
and approximately 40% of patients achieved definitive symptom 
improvement by EOC6. As previously reported, the overall (TSS) 
symptom response rate at EOC6 was 27% (24/90) (95% CI 
18%, 37%).15 Response rates for individual symptoms at EOC6 
were 36% for pain under ribs on the left side, 36% for night 
sweats, 31% for early satiety, 28% for pruritus, 26% for abdom-
inal discomfort, and 16% for bone or muscle pain (Figure 3B).
The overall symptom response rate at EOC6 was generally 
consistent across patient subgroups defined by clinically rele-
vant baseline demographic and disease characteristics, suggest-
ing minimal heterogeneity of treatment effect (Figure 5). Patient 
age at study entry was the only baseline characteristic signifi-
cantly associated with symptom response in subgroup analyses, 
with patients aged ≤ 65 years at baseline more likely to achieve 
a symptom response than those aged > 65 years (P = 0.033).
Quality of Life Core 30
At baseline, mean scores for QLQ-C30 domains were worse 
than reference values from the general population when mean 
scores were reweighted with an age-by-gender distribution 
(Table  1).24 Based on the preestablished 10-point threshold, 
scores were clinically meaningfully worse than in the general 
population in the domains of global health status/QoL, physical 
Figure 3. Proportions of patients with ≥ 50% reduction from baseline score in (A) total symptom score; and (B) individual symptom scores, on 
the modified MFSAF through the end of cycle 6.
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functioning, role functioning, cognitive functioning, social func-
tioning, fatigue, pain, dyspnea, insomnia, appetite loss, and diar-
rhea. Notably, the mean [±SD] baseline global health status/QoL 
score in JAKARTA2 was 44.6 [20.1], > 20 points lower than the 
mean score of 66.1 [21.7] in the age- and gender-matched gen-
eral population.24
Mean global health status/QoL domain score was signifi-
cantly (P < 0.01) improved from baseline at all visits through 
EOC6, exceeding the +10-point threshold for clinically mean-
ingful improvement at three timepoints (Figure  6). At EOC6, 
mean QLQ-C30 global health status/QoL domain score had 
increased by 11.1 points from baseline (mean 57.5 points) for 
patients with scores available at both visits. Effect sizes for 
changes from baseline in global health status/QoL scores ranged 
from 0.34 to 0.49, with an approximately medium effect size 
at EOC6 (0.49). Similar trends for improvement were observed 
for most other QLQ-C30 domains. Statistically significant and 
clinically meaningful improvements were reported at EOC6 in 
mean scores for physical functioning (+10.8 points), social func-
tioning (+9.4 points), and role functioning (+9.2 points); and for 
the symptom domains of appetite loss (–20.4 points), insomnia 
(–18.1 points), fatigue (–14.5 points), dyspnea (–13.2 points), 
and pain (–10.9 points). In contrast, the mean nausea and vom-
iting domain score was clinically meaningfully worsened (mean 
+10.2 points) from baseline at EOC6.
In responder analyses, 48% of patients reported clinically 
meaningful improvements from baseline in global health sta-
tus/QoL scores as early as C2D1 (Figure  7). At EOC6, 44% 
of patients reported clinically meaningful improvements from 
baseline in global health status/QoL scores, 40% reported no 
meaningful change (ie, < 10-point change from baseline score), 
and 17% reported meaningful deterioration (ie, decrease of ≥ 10 
points). In subgroup analysis, no baseline demographic or dis-
ease characteristic was significantly associated with achieving 
clinically meaningful improvement from baseline in the QLQ-
C30 global health status/QoL score at EOC6 (Figure 8).
For the 5 QLQ-C30 functional domains, proportions of 
patients experiencing clinically meaningful improvement from 
baseline at EOC6 ranged from 29% to 53%, with highest 
improvement rates in the physical functioning (53%) and social 
functioning (40%) domains, and lowest rates in the emotional 
functioning domain (29%). Among the symptom domains, the 
rate of clinically meaningful improvement at EOC6 was high-
est for fatigue (67%), and was generally low for nausea/vomit-
ing, constipation, and diarrhea domains (12%, 19%, and 17%, 
respectively).
Rates of clinically meaningful deterioration in the global 
health status/QoL score at each assessment ranged from 11% to 
19% (Figure 7). At EOC6, clinically meaningful deterioration 
rates were < 20% in all 5 functional domains, and in all symp-
tom domains except diarrhea (25%) and nausea and vomiting 
(49%) (Supplemental Digital Figure 3, http://links.lww.com/HS/
A147).
Patient’s global impression of change
The PGIC-evaluable population included 76 patients at 
C4D1, 56 patients at C6D1, and 44 patients at EOC6. Over 
80% of patients reported some improvement in MF symptoms 
(PGIC levels 1–3) at each time point, and fewer than 10% of 
patients reported worsened MF symptoms (PGIC levels 5–7) at 
any time (Supplemental Digital Figure 4, http://links.lww.com/
HS/A148). At EOC6, 84% of patients reported improvements in 
MF symptoms, 11% reported “no change,” and 4.5% reported 
worsened symptoms.
Discussion
During fedratinib treatment, patients with MF who were 
resistant or intolerant to prior ruxolitinib therapy experienced 
clinically meaningful improvements from baseline in MF symp-
tom burden, overall HRQoL, and functional status. By EOC6, 
27% of all randomized patients achieved a symptom response 
on the modified MFSAF. Of patients who were evaluable at 
EOC6, 44% experienced clinically meaningful improvement 
Figure 4. Time to ≥ 50% reduction from baseline in total symptom score on the modified MFSAF.
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on the QLQ-C30 Global health status/QoL domain, and 84% 
reported improvements in MF symptoms on the PGIC ques-
tionnaire. Although the study required only ≥ 14 days of prior 
ruxolitinib therapy for patients who were deemed resistant to 
ruxolitinib, and allowed for any duration of prior ruxolitinib 
therapy in patients who discontinued the drug due to toler-
ability problems, the actual median exposure to ruxolitinib 
prior to JAKARTA2 in HRQoL-evaluable patients was 11.1 
months,25 indicating relatively substantial ruxolitinib expo-
sure before receiving fedratinib. At study entry, patients in the 
JAKARTA2 MFSAF-evaluable population had clinical features 
consistent with advanced MF disease: median spleen volume 
(2894 mL) was ~14 times the normal volume,26 all patients 
reported experiencing MF-related constitutional symp-
toms, and one-third of patients had DIPSS-defined high-risk 
MF. Accordingly, patients in JAKARTA2 reported clinically 
meaningfully worse baseline scores on most EORTC QLQ-
C30 domains relative to an age- and gender-matched general 
population, and a higher total symptom score on the MFSAF 
compared with fedratinib-treated patients with JAK-inhibitor-
naïve MF from the phase III JAKARTA trial (mean 20.7 versus 
17.6, respectively).27
Patients reported significant and clinically meaningful 
improvements in MF symptoms on the modified MFSAF at 
all timepoints while receiving fedratinib, with more than one-
fourth of all patients achieving a ≥ 50% reduction in TSS by the 
end of the first treatment cycle. Responses were generally dura-
ble, with 38% of all patients achieving symptom responses at 
≥ 2 post baseline timepoints. The overall symptom response rate 
at EOC6 among all enrolled patients was 27%,15 with similar or 
slightly higher response rates for 5 of the 6 individual symptoms 
on the modified MFSAF, suggesting that TSS improvements were 
likely attributable to broad improvements in both spleen-related 
and constitutional symptoms.
Mean QLQ-C30 global health status/QoL domain score was 
also significantly and clinically meaningfully improved from 
baseline at each post baseline assessment with approximately 
medium effect sizes. Whereas the baseline mean global health 
Figure 5. Symptom response rates at the end of cycle 6 in patient subgroups defined by baseline demographic and disease characteristics.
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Figure 6. Mean changes from baseline in QLQ-C30 Global Health Status/QoL domain scores and corresponding effect sizes.
Figure 7. Clinically meaningful changes from baseline scores in EORTC QLQ-C30 Global Health Status/QoL scores by cycle.
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status/QoL score for patients in JAKARTA2 was 22 points 
lower than that for patients from an age- and gender-matched 
general population—a difference 2 times higher than the 
10-point threshold used to define clinically meaningful differ-
ences—patients who completed 6 fedratinib treatment cycles 
reported a mean global health status/QoL score at EOC6 of 
57.5, which was within the clinically meaningful threshold (ie, 
10 points) compared with the mean reference value from the 
general population (66.1).24 Significant and clinically meaning-
ful improvements were also observed at EOC6 in the physical, 
role, and social functioning domains, and for the symptom 
domains of fatigue, pain, dyspnea, insomnia, and appetite loss. 
Improvements in overall HRQoL during fedratinib therapy 
were achieved despite clinically meaningfully worsening from 
baseline scores in the nausea/vomiting domain. Gastrointestinal 
adverse events are known side effects of fedratinib therapy, and 
are the most common events reported in fedratinib clinical tri-
als.15,16,28 The ongoing phase IIIb FREEDOM (NCT03755518) 
and phase III FREEDOM2 (NCT03952039) studies of fedrati-
nib in patients previously treated with JAK inhibitors include 
mitigation strategies to ameliorate or prevent adverse gastro-
intestinal events associated with fedratinib, which if success-
ful, could improve patient-reported outcomes related to these 
events.
Improvements in MF symptoms and overall HRQoL in 
JAKARTA2 were observed across clinically relevant patient 
subgroups, with consistent rates of MFSAF symptom response 
across all baseline characteristic subgroups except patient 
Figure 8. Rate of clinically meaningful improvement from baseline in EORTC QLQ-C30 Global Health Status/QoL scores at the end of cycle 6 in 
patient subgroups defined by baseline demographic and disease characteristics.
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age (patients aged ≤ 65 years at study entry were significantly 
more likely to achieve a symptom response than those aged 
> 65 years), and no significant differences in rates of clinically 
meaningful improvement from baseline in global health sta-
tus/QoL, indicating an overall benefit of fedratinib therapy 
regardless of MF subtype (primary or secondary), DIPSS MF 
risk status, ECOG PS score, hemoglobin levels, platelet counts, 
JAK2 mutation status (wild-type or mutant), or extent of 
splenomegaly at study entry. Similar outcomes among patient 
subgroups are supported by results of the PGIC question-
naire, which showed that the majority (> 80%) of ongoing 
patients self-reported improvements in symptom severity and 
perceived fedratinib treatment as beneficial. It should be noted 
that patients knew they were receiving active treatment in this 
open-label study; therefore, with no control arm, there is the 
possibility that such knowledge could influence patient-re-
ported perceptions.
Results from this study show that treatment with fedratinib 
resulted in clinically meaningful improvements in MF symptom 
burden and severity, functional status, and overall HRQoL in 
patients with intermediate or high risk MF who were previously 
treated with ruxolitinib, with generally consistent treatment 
effects among patient subgroups defined by demographic and 
disease characteristics at baseline. Patient-reported outcomes 
associated with prolonged fedratinib treatment are being eval-
uated in the ongoing FREEDOM and FREEDOM2 studies in 
patients with MF for whom ruxolitinib is no longer a therapeu-
tic option.
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